Natera Inc (NTRA): A Case For Going Higher

After Hours

There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Recently, Yahoo Finance discussed the stock, revealing that Natera Acquires Reproductive Health Assets from Invitae.

Stocks Info

This NASDAQ-listed company operates within the Diagnostics & Research industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $66.68 and fluctuated between $68.92 as its day high and $65.99 as its day low. The current market capitalization of Natera Inc is $8.01B. A total of 1.35 million shares were traded on the day, compared to an average of 1.41M shares.

Insider Activity

Insider trades can also provide insight into a stock’s future direction. During the recent three months, NTRA has seen 3 BUY and 13 SELL insider trades, representing the acquisition of 1,172 and the disposition of 658,673 shares. Over the last 12 months, there were 78 BUYs and 98 SELLs from insiders. Insiders purchased 419,982 shares during that period but sold 954,808.

In the most recent transaction, Sheena Jonathan sold 5,000 shares of NTRA for 60.30 per share on Jan 03. After the transaction, the CO-FOUNDER now owns 469,743 company shares. In a previous transaction on Jan 03, Sheena Jonathan sold 1,000 shares at 60.45 per share. NTRA shares that CO-FOUNDER owns now total 21,155.

Among the insiders who sold shares, Brophy Michael Burkes disposed of 1,377 shares on Dec 29 at a per-share price of $62.29. This resulted in the CHIEF FINANCIAL OFFICER holding 64,810 shares of NTRA after the transaction. In another insider transaction, Chapman Steven Leonard sold 2,604 shares at $63.29 per share on Dec 28. Company shares held by the CEO AND PRESIDENT now total 172,348.

Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for NTRA in the last 3 months, the mean price target is $74.41 with high estimates of $117.00 and low estimates of $37.00. In terms of 52-week highs and lows, NTRA has a high of $68.59 and a low of $36.90.

As of this writing, NTRA has an earnings estimate of $Nutrien Ltd. per share for the current quarter. EPS was calculated based on a consensus of Coterra Energy Inc. estimates, with a high estimate of $Atara Biotherapeutics, Inc. per share and a lower estimate of $Intellia Therapeutics, Inc.

Balance Sheet Annually/Quarterly

In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. NTRA’s latest balance sheet shows that the firm has $914.28M in Cash & Short Term Investments as of fiscal 2021. There were $397.23M in debt and $218.96M in liabilities at the time. Its Book Value Per Share was $6.59, while its Total Shareholder’s Equity was $653.30M.

Analysts Opinion

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for NTRA is Buy with a score of 4.79.